Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Search
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Human Pharma Research & Development Approach
Human Pharma Research & Development Approach
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Innovation & Opportunity for Tech in Pharma
Boehringer Ingelheim’s Meet & Greet at the Women in Tech Global Conference
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
Smart Biopharmaceutical Process Development
Smart Biopharmaceutical Process Development
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Distributing medicine globally with pharmaceutical logistics
From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Pipeline Overview
Boehringer Ingelheim Human Pharma Clinical Pipeline
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Boehringer Ingelheim announces appointments Board of Managing Directors
Boehringer Ingelheim announces appointments Board of Managing Directors
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”